Pfizer

Current directors and officers who also hold a role at another S&P 500 company.

• David M. DentonHONA · DirectorNKE · CFO
• Johnson Suzanne M. NoraINTU · DirectorNVDA · Director
• Scott GottliebILMN · DirectorUNH · Director
• James QuinceyKO · Chair
• Joseph EchevarriaBNY · Director
• Lidia FonsecaMDT · Director
• Mortimer J. BuckleyBA · Director
• Ronald E. BlaylockWRB · Director
• Shantanu NarayenADBE · CEO

Latest Schedule 13D/13G filing per holder. Holders that reported falling below 5% are not shown. Index funds usually report once a year.

No 5% holder filings parsed yet for this company.

Open-market purchases and sales reported on Form 4. Grants, option exercises and tax withholding are excluded.

Every 8-K with Item 5.02 (departure, election or appointment of directors and officers). The text is the first paragraph of the item.

1. Nov 3, 2026

   On November 3, 2026, Pfizer Inc. (the “Company”) announced that the Board of Directors of the Company unanimously elected Cecile Guegan to serve as Chief Financial Officer, Executive Vice President of the Company, effective November 1, 2026 (the “Effective Date”). As reported in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on June 18, 2026, Ms. Guegan, 55, was previously appointed as the Company’s Interim Chief Financial Officer, effective August 16, 2026. Ms. Guegan has more than 25 years of global finance leadership in the pharmaceutical industry. She joined Pfizer in connection with its 2009 acquisition of Wyeth, where she had served as chief financial officer supporting the Asia Pacific and EMEA/Canada businesses.

   Read the 8-K filing
2. Jun 18, 2026

   On June 16, 2026, Dave Denton notified Pfizer Inc. (the “Company”) that he will step down from his current position as Chief Financial Officer effective August 15, 2026 for a professional opportunity outside of the pharmaceutical industry in consumer goods, and that his departure is not related to the Company’s financial or operating results or to any disagreements with the Company regarding the Company’s financial, operational, accounting or reporting policies or practices. In connection with Mr. Denton’s departure, the Company announced that Cecile Guegan, the Company’s Senior Vice President, Finance, Global Biopharmaceutical Business, will serve as Interim Chief Financial Officer, effective August 16, 2026, while the Company conducts a comprehensive process to identify Mr. Denton’s successor. Ms. Guegan, 55, joined Pfizer in 2005 and has served in her current role since 2022.

   Read the 8-K filing
3. Oct 15, 2024

   Election of Mr. Buckley to the Board of Directors On October 10, 2024, the Board of Directors (the “Board”) of Pfizer Inc. (the “Company”) elected Mortimer J. Buckley to serve as a member of the Company’s Board, effective immediately. In addition, he was elected to the Governance & Sustainability Committee and the Audit Committee of the Board. Mr. Buckley has been provided an indemnification agreement and will receive compensation, each in accordance with the Company’s standard arrangements for non-employee directors. The press release, dated October 10, 2024, announcing the election of Mr. Buckley is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

   Read the 8-K filing
4. Jul 26, 2024

   Modifications to Five-Year Total Shareholder Return Units and Performance Share Awards As disclosed in

   Read the 8-K filing
5. Jul 10, 2024

   On July 9, 2024, Pfizer Inc. (the "Company") announced that it is beginning the process of finding a successor for Dr. Mikael Dolsten, the Company’s Chief Scientific Officer and President, Pfizer Research & Development after his more than 15-year distinguished career with the Company. The Company has initiated an external search for a new Chief Scientific Officer. Dr. Dolsten will continue to serve in his current position until his successor is in place and any necessary transition is complete. It is anticipated that Dr. Dolsten will remain with Pfizer through at least February 28, 2025.

   Read the 8-K filing
6. Jul 1, 2024

   Election of Mr. Taraporevala to the Board of Directors On June 27, 2024, the Board of Directors (the “Board”) of Pfizer Inc. (the “Company”) elected Cyrus Taraporevala to serve as a member of the Company’s Board, effective immediately. In addition, he was appointed to and will join the Audit Committee and the Compensation Committee of the Board. Mr. Taraporevala has been provided an indemnification agreement and will receive compensation in accordance with the Company’s standard arrangements for non-employee directors. The press release, dated July 1, 2024, announcing the election of Mr. Taraporevala is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

   Read the 8-K filing
7. Dec 12, 2023

   On December 12, 2023, Pfizer Inc. (“Pfizer” or “the Company”) announced that given the size and geographic scope of Pfizer’s commercial operations and the anticipated close of the acquisition of Seagen Inc. (“Seagen”), the following changes to its commercial operations will become effective on January 1, 2024. Pfizer will create an end-to-end business organization called Pfizer Oncology Division, which will integrate certain Oncology Commercial and R&D operations from both Pfizer and Seagen and will be led by Dr. Chris Boshoff, who will become Chief Oncology Officer, Executive Vice President, and continue reporting to Dr. Albert Bourla, Chairman and Chief Executive Officer. Pfizer will split its non-oncology commercial organization into two more focused business divisions: the Pfizer U.S. Commercial Division, which will be led by Aamir Malik, who will become Chief U.S.

   Read the 8-K filing
8. Jul 27, 2023

   On July 27, 2023, Pfizer Inc. (“Pfizer” or “the Company”) announced that in consideration of planned future investments in Oncology, including the proposed acquisition of Seagen Inc., it is restructuring its Research and Development organization with Oncology as a stand-alone unit. Effective immediately, Dr. Chris Boshoff, currently Chief Development Officer – Oncology, will become Chief Oncology Research and Development Officer, Executive Vice President, and the remainder of our early and late-stage development will be consolidated and led by Dr. Mikael Dolsten, Chief Scientific Officer and President, Pfizer Research and Development. As a result of this reorganization, the role held by Dr. William Pao, Chief Development Officer, Executive Vice President, is being eliminated and he will leave the Company effective August 15, 2023.

   Read the 8-K filing
9. Apr 12, 2022

   On April 11, 2022, Pfizer Inc. (the “Company”) announced that the Board of Directors of the Company elected David M. Denton as Chief Financial Officer, Executive Vice President of the Company and appointed Mr. Denton as a member of the Company's Executive Leadership Team, effective May 2, 2022 (the “Effective Date”). Prior to joining the Company, Mr. Denton, 56, served as Executive Vice President, Chief Financial Officer of Lowe’s Companies, Inc. Mr. Denton joined Lowe’s in 2018. Mr. Denton has more than 25 years of finance and operational expertise, including more than 20 years in the healthcare sector. Prior to joining Lowe's in 2018, Mr. Denton served as Executive Vice President and Chief Financial Officer of CVS Health since 2010, where he was responsible for all aspects of their financial planning and management.

   Read the 8-K filing
10. Dec 15, 2021

    On December 9, 2021, the Compensation Committee of the Board of Directors of Pfizer Inc. approved changes under the Pfizer Inc. Global Performance Plan, Amended and Restated January 2021 (Bonus Plan). The purpose of the company’s Bonus Plan is to provide the company’s executive officers and other participating employees, with an opportunity to earn annual cash incentive compensation based on individual performance from a bonus pool that is funded based on the achievement of preselected financial and pipeline performance goals over the performance year. The annual bonus is funded based on Pfizer’s performance against the financial and pipeline performance goals and the Bonus Plan pool funding may range from 0% to 200% of the aggregate target bonuses for the participants. Individual bonuses have been capped at 200% of the individual’s target bonus.

    Read the 8-K filing
11. Nov 19, 2021

    On November 17, 2021, Pfizer Inc. ("Pfizer" or the "Company") announced that Frank D'Amelio will retire from his position as Chief Financial Officer and Executive Vice President of Global Supply after nearly 15 years of distinguished service with the company. Pfizer has initiated an external search for a new Chief Financial Officer. Mr. D'Amelio will continue to serve as CFO until his successor is in place. Mr. D'Amelio made the following statement in connection with this announcement, "It’s been a privilege and a pleasure to work with Albert Bourla and my Pfizer colleagues. I remain a tremendous supporter of the Company, its leadership and direction." Mr. D'Amelio led both the Finance and Pfizer Global Supply ("PGS") functions, having been asked by the Company to take on PGS in 2019.

    Read the 8-K filing
12. Jul 9, 2021

    John D. Young, Group President, Chief Business Officer, has announced his decision to retire from Pfizer Inc. (the “Company”) in early 2022. He will be stepping down as an executive officer no later than December 31, 2021, after which he will remain as an employee of the Company in an advisory role for a period of time in 2022.

    Read the 8-K filing
13. Nov 20, 2020

    Effective as of November 16, 2020, in connection with the Transactions, each of James Kilts and W. Don Cornwell joined the Viatris Board of Directors and resigned from Pfizer’s Board of Directors.

    Read the 8-K filing
14. Apr 2, 2020

    Election of Dr. Susan Desmond-Hellmann to the Board of Directors On April 1, 2020, the Board of Directors (the “Board”) of Pfizer Inc. (the “Company”) elected Susan Desmond-Hellmann to serve as a member of the Company’s Board, effective immediately. In addition, she was elected to the Governance & Sustainability Committee and the Science and Technology Committee of the Board. Dr. Desmond-Hellmann has been provided an indemnification agreement and will receive compensation in accordance with the Company’s standard arrangements for non-employee directors. The press release, dated April 2, 2020, announcing the election of Dr. Desmond-Hellmann is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

    Read the 8-K filing
15. Mar 4, 2020

    Election of Dr. Susan Hockfield to the Board of Directors On March 3, 2020, the Board of Directors (the “Board”) of Pfizer Inc. (the “Company”) elected Susan Hockfield to serve as a member of the Company’s Board, effective immediately. In addition, she was elected to the Regulatory and Compliance Committee and the Science and Technology Committee of the Board. Dr. Hockfield has been provided an indemnification agreement and will receive compensation in accordance with the Company’s standard arrangements for non-employee directors. The press release, dated March 4, 2020, announcing the election of Dr. Hockfield is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

    Read the 8-K filing

Proxy statements (DEF 14A): 2026 · 2025 · 2024 · 2023 · 2022 · 2021

From the company's 10-K XBRL data (SEC companyfacts).

People who stopped filing as an insider of this company. “Last filing” is the last Form 3/4/5, an upper bound on when they left.